175
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Cost–effectiveness of treatments for high-risk myelodysplastic syndromes after failure of first-line hypomethylating agent therapy

, , , , , , & show all

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Eytan M. Stein, Gaetano Bonifacio, Dominick Latrémouille-Viau, Sherry Shi, Annie Guérin, Eric Q. Wu, Islam Sadek & Xiting Cao. (2021) Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis. Journal of Medical Economics 24:1, pages 234-243.
Read now

Articles from other publishers (3)

Leylah M. DrusboskyNeeraj Kumar SinghKimberly E. HawkinsCesia SalanMadeleine TurcotteElizabeth A. WiseAmy MeachamVindhya VijayGlenda G. Anderson, Charlie C. KimSaumya RadhakrishnanYashaswini UllalAnay TalawdekarHuzaifa SikoraPrashant NairArati Khanna-Gupta, Taher AbbasiShireen ValiSubharup GuhaNosha FarhadfarHemant S. Murthy, Biljana N. Horn, Helen L. LeatherPaul Castillo, Caitlin TuckerChristina ClineLeslie PettifordJatinder K. Lamba, Jan S. MorebRandy A. BrownMaxim NorkinJohn W. HiemenzJack W. HsuWilliam B. Slayton, John R. WingardChristopher R. Cogle. (2019) A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients. Blood Advances 3:12, pages 1837-1847.
Crossref
Isabella Pallotto & John D. Lantos. (2017) Treatment Decisions for Babies with Trisomy 13 and 18. HEC Forum 29:3, pages 213-222.
Crossref
Christopher R. Cogle, Sandra E. Kurtin, Tanya G. K. Bentley, Michael S. Broder, Eunice Chang, Scott Megaffin, Steven Fruchtman, Michael E. Petrone & Sudipto Mukherjee. (2017) The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First-Line Hypomethylating Agents Fail. The Oncologist 22:4, pages 379-385.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.